Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alzheimer's Biomarkers Gain Prominence In Drug Development Guidance

Feb 16 2018

• By Brenda Sandburg

Memory loss and brain aging due to dementia and alzheimer's disease as a medical icon of a group of color changing autumn fall trees shaped as a human head losing leaves on a white background.

Related Content

Disease-Specific Guidances Reflect US FDA's 'Nimble, Collaborative, Patient-Focused' Approach

Feb 16 2018

Biogen Spooks With Phase III Aducanumab Changes

Feb 15 2018

M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed

Feb 14 2018

Related Companies

Eli Lilly and Company

Merck & Co., Inc.

Biogen, Inc.

Additional Topics

United States Drug Approval Standards Clinical Trials Research & Development Regulation FDA Neurology BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window